Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Highly experienced ex-Delta One trader with 17 years of experience trading arbitrage and related strategies across Asian markets.

Exempt Financial Adviser (EFA) under CrossASEAN Research Pte Ltd.

It is important to note that the information provided by Periscope Analytics is based on publicly available data and own knowledge, which has been gathered and synthesized from a variety of sources. While every effort has been made to ensure the accuracy and completeness of the information provided, it is not guaranteed to be free from errors or omissions.

All forecasts and estimates are based on information that has been obtained from public sources that are considered to be reliable. The sources include, but are not limited to, company announcements, exchange filings, ETF and other passive investment vehicle holdings, and free float and volume data from third-party data providers. Periscope Analytics does not guarantee the accuracy and completeness of the forecasts, estimates and/or other information.

Pan-Asia Index Rebalances/ Events/ Delta One

KOSPI200 Index Rebalance Preview - Positioning Begins for December

SK Biopharmaceuticals - Index Fast Entry Possibilities: KOSPI200, FTSE, MSCI

FTSE GEIS Index Rebalance Preview September 2020 - Korea

SK Biopharm IPO Industry Analysis & Contract Details

SK Holdings SoTP Valuation Sensitivity Analysis

Event-Driven

<p><a href="https://www.smartkarma.com/entities/sk-biopharmaceuticals-co-ltd" target="_blank" rel="noopener" data-smartkarma-citation="entities:28966:1">SK Biopharmaceuticals (BIO SK)</a> could reopen the Korean IPO market with its listing that is expected later this month. With 19.58m shares being offered in the IPO at a price range of KRW 36,000 - KRW 49,000 per share, there is a possibility that the stock could get fast entry into the <a href="https://www.smartkarma.com/entities/korea-stock-exchange-kospi-200-index" target="_blank" rel="noopener" data-smartkarma-citation="entities:26021:1">Korea Stock Exchange Kospi 200 Index (KOSPI2 INDEX)</a> and other global indices bringing in passive flows and supporting the stock price.</p><p>In this Insight, we take a look at a few details of the IPO and assess the likelihood of the stock getting fast entry into indices that have significant assets benchmarked to them.</p>

SK Biopharmaceuticals (BIO SK) could reopen the Korean IPO market with its listing that is expected later this month. With 19.58m shares being offered in the IPO at a price range of KRW 36,000 - KRW 49,000 per share, there is a possibility that the stock could get fast entry into the Korea Stock Exchange Kospi 200 Index (KOSPI2 INDEX) and other global indices bringing in passive flows and supporting the stock price.In this Insight, we take a look at a few details of the IPO and assess the likelihood of the stock getting fast entry into indices that have significant assets benchmarked to them.

Korea Stock Exchange KOSPI 200 (KOSPI2 INDEX EQUITY)

SK Biopharmaceuticals - Fast Index Entry Possibilities